Quarterly ResultMay 14, 2026, 04:10 PM
Cue Biopharma Appoints New CEO; Secures $30M Financing & Licenses CUE-221
AI Summary
Cue Biopharma reported Q1 2026 financial results, including revenue of $5.7 million and a net loss of $5.2 million. The company announced the appointment of Shao-Lee Lin as President, CEO, and Board Director, and strengthened its financial position with a $30 million private placement and a $7.5 million milestone payment from Boehringer Ingelheim. Additionally, Cue Biopharma enhanced its pipeline by exclusively licensing CUE-221, a Phase 2 program for allergic disease, and outlined upcoming clinical milestones for CUE-221 and CUE-401 in the second half of 2026.
Key Highlights
- Shao-Lee Lin appointed President, CEO, and Board Director.
- Completed $30 million private placement to fund clinical pipeline.
- Received $7.5 million milestone payment from Boehringer Ingelheim collaboration.
- Licensed CUE-221, a Phase 2 program for allergic disease.
- Q1 2026 revenue was $5.7 million, up from $0.4 million YoY.
- Q1 2026 net loss was $5.2 million, down from $12.3 million YoY.
- Cash and cash equivalents totaled $16.4 million as of March 31, 2026.
- Expects CUE-221 and CUE-401 IND submissions in H2 2026.